DIN 02505614 — TAKHZYRO 300 MG
TAKHZYRO is a solution of Lanadelumab marketed by TAKEDA CANADA INC. The full Lanadelumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02505614
- Brand name
- TAKHZYRO
- Active ingredient
- Lanadelumab
- Strength
- 300 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- TAKEDA CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Monoclonal antibody plasma kallikrein inhibitor (biologic)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Lanadelumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02480948 | TAKHZYRO | 300 MG | SOLUTION | TAKEDA CANADA INC | MARKETED |
| 02564483 | TAKHZYRO | 300 MG | SOLUTION | TAKEDA CANADA INC | MARKETED |